FDA Approves Enlicitide Pill That Cuts LDL by Nearly 60% as Heart Disease Kills 694,708 Americans
Updated
Updated · Vox.com · Jul 25
FDA Approves Enlicitide Pill That Cuts LDL by Nearly 60% as Heart Disease Kills 694,708 Americans
3 articles · Updated · Vox.com · Jul 25
Summary
Enlicitide won FDA approval last week as a once-daily pill that lowers LDL cholesterol by nearly 60%, matching the potency of leading injectable PCSK9 drugs without requiring needles or specialist prescribing.
PCSK9 drugs work by mimicking a naturally occurring mutation first identified in the Dallas Heart Study, where carriers had about 28% lower LDL and roughly 88% lower heart-disease risk.
The pill targets patients who cannot tolerate statins or fail to lower LDL enough with them, but its own trial proving reductions in deaths, heart attacks or strokes will not finish for years.
Access may limit its impact: enlicitide is priced at about $300 a month, insurance coverage is uncertain, and about half of statin patients stop treatment within a year.
The approval lands amid broader progress against cardiovascular disease, whose US age-adjusted death rate has fallen about three-quarters since 1950 even as heart disease still causes about one in five deaths.
Will this new $315-a-month cholesterol pill actually prevent heart attacks, or are patients paying a premium just to fix a lab number?
If a simple pill replaces injections, will it finally solve the massive adherence gap, or will insurance hurdles keep it out of reach?
With plant-based diets proving highly effective for cholesterol, are we over-relying on expensive daily pills instead of addressing root lifestyle causes?
FDA Approves Lipfendra (Enlicitide) as First Oral PCSK9 Inhibitor: Clinical Breakthroughs, Access Barriers, and the Future of Cholesterol Management
Overview
Lipfendra (enlicitide), approved by the FDA in July 2026, is the first oral PCSK9 inhibitor for lowering LDL cholesterol in adults with hypercholesterolemia. Enlicitide works by binding to the PCSK9 protein, blocking its interaction with LDL receptors on liver cells. This prevents receptor degradation, allowing more receptors to recycle and clear LDL cholesterol from the blood. The drug is formulated with sodium caprate to help it pass through the intestinal lining, but must be taken on an empty stomach for proper absorption. Clinical trials showed powerful LDL-C reductions, and its lower price compared to injectables may improve patient access, though long-term outcome data are still pending.